Equities analysts forecast that Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) will announce earnings per share of ($0.47) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Imago BioSciences’ earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.50). Imago BioSciences posted earnings of ($8.13) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 94.2%. The business is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Imago BioSciences will report full year earnings of ($1.91) per share for the current fiscal year, with EPS estimates ranging from ($2.04) to ($1.66). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.46) per share, with EPS estimates ranging from ($3.13) to ($1.90). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Imago BioSciences.
Imago BioSciences (NASDAQ:IMGO – Get Rating) last announced its quarterly earnings data on Thursday, March 24th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.06).
In other Imago BioSciences news, insider Laura G. Eichorn sold 8,000 shares of the stock in a transaction that occurred on Tuesday, February 22nd. The stock was sold at an average price of $21.60, for a total value of $172,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMGO. Metropolitan Life Insurance Co NY bought a new stake in shares of Imago BioSciences in the 1st quarter worth $28,000. Citigroup Inc. bought a new stake in shares of Imago BioSciences in the third quarter worth $30,000. Ameritas Investment Partners Inc. grew its holdings in Imago BioSciences by 108.3% during the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company’s stock valued at $30,000 after purchasing an additional 809 shares during the period. Morgan Stanley bought a new stake in Imago BioSciences during the third quarter valued at about $50,000. Finally, Legal & General Group Plc grew its holdings in Imago BioSciences by 248.3% during the fourth quarter. Legal & General Group Plc now owns 3,166 shares of the company’s stock valued at $75,000 after purchasing an additional 2,257 shares during the period. Institutional investors and hedge funds own 88.28% of the company’s stock.
Shares of Imago BioSciences stock opened at $14.71 on Monday. The business’s 50-day moving average price is $18.23 and its 200-day moving average price is $20.49. Imago BioSciences has a 12 month low of $12.85 and a 12 month high of $35.68.
About Imago BioSciences (Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.